Quantcast
Last updated on April 20, 2014 at 14:04 EDT

Latest gabapentin Stories

2012-06-12 02:26:08

MENLO PARK, Calif., June 12, 2012 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the Wells Fargo Securities Healthcare Conference in Boston. The presentation at the Wells Fargo conference is scheduled for 9:30 am EDT (6:30 am California time) on Tuesday, June 19, 2012. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcast will be...

2012-06-06 02:25:27

MENLO PARK, Calif., June 6, 2012 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced the issuance of a new patent expanding the patent estate around the company's Gralise® (gabapentin), Depomed's once-daily gabapentin product approved for the management of postherpetic neuralgia. The patent, United States Patent No. 8,192,756, expires in October 2022 and will be listed in the FDA "Orange Book" along with the six patents currently listed for Gralise. "We are particularly pleased...

2012-05-25 02:21:29

MENLO PARK, Calif., May 25, 2012 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the Jefferies Global Health Care Conference in New York City. The presentation at the Jefferies conference is scheduled for 10:30 am EDT (7:30 am California time) on Monday, June 4, 2012. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcast will be...

2012-05-24 23:17:22

UCSF scientists aim to use embryonic stem cells for treatment Chronic pain, by definition, is difficult to manage, but a new study by UCSF scientists shows how a cell therapy might one day be used not only to quell some common types of persistent and difficult-to-treat pain, but also to cure the conditions that give rise to them. The researchers, working with mice, focused on treating chronic pain that arises from nerve injury -- so-called neuropathic pain. In their study, published...

2012-05-10 02:31:42

MENLO PARK, Calif., May 10, 2012 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced that it will be presenting at the Bank of America Merrill Lynch Health Care Conference in Las Vegas, Nevada. The presentation at the B of A conference is scheduled for 3:00 pm EDT (12 noon California time) on Wednesday, May 16, 2012. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the...

2012-05-02 02:28:05

ATLANTA, May 2, 2012 /PRNewswire/ -- Acella Pharmaceuticals, LLC, a specialty pharmaceutical company, announces the approval of an Abbreviated New Drug Application (ANDA) for Gabapentin Oral Solution, 250 mg/5 mL. The Food and Drug Administration (FDA) determined that Acella's ANDA is bioequivalent - therefore, therapeutically equivalent - to the reference listed drug, Neurontin®* Oral Solution, 250 mg/5 mL. "Acella looks forward to adding Gabapentin Oral Solution to our existing line...

Anticonvulsant Drug Helps Marijuana Smokers Kick The Habit
2012-04-24 10:40:34

Scientists at The Scripps Research Institute have found clinical evidence that the drug gabapentin, currently on the market to treat neuropathic pain and epilepsy, helps people to quit smoking marijuana (cannabis). Unlike traditional addiction treatments, gabapentin targets stress systems in the brain that are activated by drug withdrawal. In a 12-week trial of 50 treatment-seeking cannabis users, those who took gabapentin used less cannabis, experienced fewer withdrawal symptoms such as...

e4ed0fb545995ffbe4138bdd0ac7c155
2011-06-29 05:45:00

A clinical trial of gabapentin, an epilepsy drug, may have been a "seeding trial" that was used by the pharmaceutical company purely for promotional purposes and to increase prescriptions, according to researchers from Yale School of Medicine. Joseph Ross, M.D. and his colleagues at Yale describe a seeding trial as "a clinical trial conducted primarily for marketing purposes and intended to promote the drug and increase prescribing by exposing physician-investigators to it." Researchers from...

2011-04-12 08:07:52

(Ivanhoe Newswire) -- The American Academy of Neurology has issued a new guideline on the most effective treatments for diabetic nerve pain -- the burning or tingling pain in the hands and feet that affects millions of people with diabetes. Diabetic nerve pain, or neuropathy, is caused by nerve damage. "When neuropathy strikes, it is painful and can disrupt sleep; because of this, it can also lead to mood changes and lower quality of life," lead guideline author Vera Bril, MD, FRCP, with the...

2011-04-07 07:02:00

SILVER SPRING, Md., April 7, 2011 /PRNewswire-USNewswire/ -- On April 6, the U.S. Food and Drug Administration approved Horizant Extended Release Tablets (gabapentin enacarbil), a once-daily treatment for moderate-to-severe restless legs syndrome (RLS). (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) RLS is a disorder that causes a strong urge to move the legs. This urge often occurs with unpleasant feelings in the legs. People who have RLS describe feeling pulling, itching,...